User shared 3-week progress using Pyrilutamide once a day for hair loss. Another user shared their 3-month progress with 0.25% concentration Pyrilutamide, experiencing rollback of 4 years in 3 months.
The conversation discusses a user's positive experience with a hair loss treatment routine involving dutasteride, oral minoxidil, and Nourkrin Man, with no side effects reported. Other users share their experiences with similar treatments, discussing side effects like heart palpitations and depression, and offer advice on obtaining prescriptions affordably.
RU58841 is being considered for hair maintenance by someone who can't tolerate finasteride. Alternatives like topical finasteride, dutasteride, and KX826 are also suggested.
The conversation discusses the effectiveness of commercial Low-Level Laser Therapy (LLLT) devices for hair growth, suggesting they are underpowered compared to the ideal energy output shown in medical research. A user plans to build a custom helmet that meets the required specifications for effective treatment.
The conversation discusses whether using pyrilutamide would interfere with minoxidil's ability to regrow hair, considering pyrilutamide is seen as a maintenance drug that stops shedding, while minoxidil promotes hair growth but causes initial shedding.
GHK-Cu is discussed as a potential hair loss treatment, with claims of promoting hair growth and possibly reversing gray hair, though strong clinical evidence is limited. The user also mentions using Minoxidil, red light therapy, and microneedling.
The user is undergoing Mesotherapy and Low-Level Laser Therapy for hair loss, with plans for multiple sessions. They are also using oral finasteride, topical minoxidil, dutasteride, and hair fibers.
A 35-year-old male uses topical minoxidil, spironolactone, and microneedling for hair loss, with spironolactone prescribed based on a DNA test indicating poor response to finasteride and dutasteride. Despite concerns about the test's validity and spironolactone's side effects, he reports stable or improved hair condition and no low testosterone symptoms.
Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.
Researching the effectiveness of the hair loss treatment Pyril in comparison to other treatments such as Minoxidil, Finasteride, and RU58841. Replies suggest that users often fail to provide updates on their experience with Pyril.
The conversation is about adding a topical anti-androgen to a hair loss treatment regimen that includes dutasteride and oral minoxidil. The user is considering topical finasteride or dutasteride, Nizoral shampoo, KX-826, and topical spironolactone, while avoiding RU58841 due to safety concerns.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.
A user is seeking a trusted supplier for RU58841 in the UK, expressing doubts about their current source, rudirect, and considering Anagenic and receptorchem. They are asking for recommendations for other suppliers.
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.
A user discusses using latanoprost, a costly treatment that may extend the hair growth phase and improve hair quality, wondering why it's not more popular. They already use a combination of finasteride and minoxidil and plan to incorporate latanoprost into their routine.
A user has been using dutasteride, RU58841, minoxidil, and ketoconazole for 2 years with no progress and worsening hair recession. They seek advice on how to proceed.
RU58841 alone had mixed results; some users combined it with minoxidil. One user experienced side effects with finasteride and maintained with RU58841 and minoxidil, but noted possible chest pain.
Obtaining treatments for hair loss that are not approved in one's own country, such as pyrilutamide or GT20029. It was suggested to use a middleman to get it, but there is the risk of getting low quality or fake products.
The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.
The user has been treating hair loss for a year using Hims topical finasteride/minoxidil, derma stamping, and RU58841, with plans to continue and hopes for more significant results. They have noticed some small hair growth at the temples and will provide updates on their progress.
A user's six month progress with Pyrilutamide, a hair loss treatment; they experienced positive results such as stopped itching and shedding, as well as regrowth, without any side effects.
A user shared their positive experience with the Omnilux Red Light mask for skin and potential hair benefits, while also using Minoxidil, Dutasteride, and RU58841. They recommend the mask for those interested in skincare and red light therapy, despite being unsure of its effectiveness for hair growth.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.